
The price for Novo Nordisk’s new obesity drug, Wegovy, is not equal to its therapeutic effect, assesses the Danish Reimbursement Committee, which advises the Danish Medicines Agency.
The committee is therefore recommending to the agency that Novo Nordisk’s reimbursement application for Wegovy be rejected, according to Danish media Berlingske.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app